Hi I’m Graeme McFarland. I’m the chief commercial officer for Albert Labs. Albert Labs was formed specifically for this task and the task is this that we want to bring psilocybin to the UK and Europe and the research setting that we call real-world evidence and actually get. Patient access to this. I’ve been watching this.

They’ll be looking at this over the last few weeks and months. This particular area of concert related anxiety is a huge unmet need. And I mean, a huge unmet need. There are patients out there that are suffering today. If we took the traditional route of a clinical trial, you know, which frankly is unnecessary because we already know what the active ingredient is.

But if we took that route, those same patients will be waiting six, seven years to get access. Only the people with the patients who are in the trial would have access over that period. If you like. And that’s a small number compared to that whole population, the UK alone has 1.2 million patients in the UK, 30 to 40% that represents of cancer patients who also have anxiety.

And that’s understandable if you were told tomorrow that you’ve got cancer, you know, you’re not going to go sing it and dance near the door. You’re going to be subtly upset by them. And we can do something about that and we can do it today. And that’s my point. And that’s why I’m here. That’s why Albert loves exists.

We want to get us in front of the patients. Now

as you know, the, um, national agenda for cancer is very, it’s very high in the UK. As has mental health, both have been experiencing a lot of investment on service redesign. And that’s where I live. I was from the pharmaceutical industry and biotech. Uh, much of our work was that seeing complex specialist medicines difficult to bring to market, uh, but very, very important for the patient groups who we’re dealing with.

So patients who have mental health issues and also cancers. So it’s an area I’m familiar with and, um, working in Albert Lab some of that learning is applicable to what we’re trying to do here and bring in what is a novel therapy. To a market that is largely an unmet need.

Well, the evidence is as it, as it describes, it all happens out there in the world setting. If you like that world to be in the clinic setting where patients will actually talk to talk. With their therapist, their doctor, and other people who are experts. If you can compare that with, uh, random clinical trials RCTs, they tend to be lengthy, I mean, many years.

Uh, and they’re also designed to identify whether they’re identified molecule, which the companies, the pharma companies, and the biotech I’ve developed through the lab setting to allow them to actually look at it and see if it actually works. We have, um, Decades, if not thousands of years of experience here with the drug we were talking about, uh, and we don’t need to do that.

We can go straight to patient level evaluation and that works best if you’re actually in the clinic setting where the patient actually goes to get the treatment, it shows the processes, it reflects the outcomes, not just in a clinical setting, but also in the real world with, with the clinician, treating them and patient feedback as well.

So we’re getting the whole round, if you like. Experience of what the patient goes through from foster introduction to outcome and that’s real world, and it wouldn’t exist unless we had data to support that. And we do have big data now, which allows us to do this

Constant related anxiety. Meets a number of high priorities for the UK government and the healthcare system. That’s the fact cancer’s on the national agenda as is mental health. We’ve chosen that because of those two facets, but also because the patients involved need treatment. This is an unmet need.

This is a term that’s used a lot in health, but this is an unmet need. You know, for many, many years, mental health was regarded as the Cinderella service, right. There was nothing going into it. There is no. And that allows us to do this. Processes are getting better. Psychotherapy is more informed. Now people know what they’re dealing with and all the proof there says that we can actually make a difference to that.

The good thing I find about this whole area, right, is that we, by choosing the real world evidence route, we can actually bring our drug to market much quicker than we’d be the KC. We actually went into the clinical trial. And that’s, that’s important. That’s really important because the patients who want to wait tomorrow or seven years, they would, they would actually benefit from it now.

Well, let’s not forget these patients are suffering from cancer. They’re uncommitted therapists have been treated for other matters. Okay. We’re trying to leave this site, the anxiety, the depression, say more the anxiety. When you go a family that you can no longer connect with, you don’t know how to love, right?

You don’t know to actually socialize anymore. Everything’s very inward. It’s very insular. You’re closed off and you actually see it as a patient, right? The oxygen closing off they’re hurting people. Okay. Treat the patient. You’re treating the family as well. You’re seeing the partners, you’re treating the kids.

You’re treating them. Right, but not to music.

Corpus. All of the real world evidence studies is many fold. I mean, primarily it starts to show the eight works, what we’re doing and actually helps patients. Right. But beyond that, it creates a patient cohort that comes through a particular unit. We have five units set up in the UK already. Um, we are, we are those attractive patients that way the patients in this study, we are paying for the drug.

Okay. That’s a, that’s a given when the trial ends and if they need more, after that, there’s a follow on treatment pathway, then there’ll be paying for that. There’ll be paying that through the specialist, but the big part of this is establishing habits. All right. So the clinicians see this works. They want to use it.

They want to prescribe it. That’s when we made money, they prescribed the NHS, pays us for the parks and we’re making money. Okay. And that is forecast to happen at one to six. Not the book.

We will be publishing of course. Right. And that starts with the protocol. Right. If you publish the protocol, you’re seen to be ethical. Okay. And that’s a fact that most companies do that and that’s a good thing. Well, the Alyssa does for us is it provides PR that we’re actually heading in this direction and we’ll see us.

Okay. So publishing is good. Publishing the protocol also attracts interest to people. So there are centers there that we may not be in contact with who say, I’m interested in becoming part of the trial. Can you please advise how we do that? So you’re doing numbers of things there, but you’re setting up when you start talking about our Wes and IP to Albert labs is starting to set up your IP there.

Okay. We are different. We’re doing this. We’re going to own this data at the end of it and we’re going to publish. Okay. And then we become to publish again. It will go in the British journal of medicine. It will go into Lansette I’ll go into the, the cream, the top end. Yeah. Uh, and that gives us huge kudos.

You can’t. And this is back to IP. You can’t claim a class effect for a drug that has been researched to subtly assess and a patient cohort that we selected. Okay. So if there’s anybody out there producing this or something similar, or probably a different dose range, that’s almost out because we’ll have a different dose range, right?

They can’t claim class effect. The IP is protected because we’ve actually done the right things from the very first step. We all know that we own the data.

sticking to real well, definitely for all the reasons I gave this is about speed to getting in front of patients, making sure they get it. Can’t do this six or seven years waiting, knowing that somebody’s available, you can actually, Brent, uh, it’s, it’s not our behavior. You know, we’re different. We, we want to behave in an ethical manner.

We care about what happens. We want the patient at the end of the day to be better.